Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06776081 · ClinicalTrials.gov registry record · NA

Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function

A NA study of Obesity and Weight Loss, sponsored by University of Colorado, Boulder.

Recruiting
Registry status
NA
Development phase
84
Enrollment target
1
Study location

NCT06776081: Recruiting NA study of Obesity and Weight Loss, sponsored by University of Colorado, Boulder.

NCT06776081 is a NA study of Obesity and Weight Loss that is actively recruiting participants, run by University of Colorado, Boulder. The registered enrollment target is 84 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06776081, a NA study of Obesity and Weight Loss, is actively recruiting participants, sponsored by University of Colorado, Boulder.

RECRUITING
Registry status
NA
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity. The investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.

Primary Outcome

Circulating Ad-EVs will be determined from a peripheral blood sample in normal weight and obese adults. Ad-EVs will be determined using flow cytometry. The samples will be incubated with perilipin A. Ad-EVs will be defined as perilipin A positive cells ranging in size 0.2-0.8 um.

Conditions Studied

Interventions

  • OTHER Weight loss without pharmacotherapy

Study Locations (1)

Colorado

  • University of Colorado Boulder Clinical and Translational Research Center (CTRC) - Boulder

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2024-07-01
Est. Completion 2027-06-30
Phase NA
University of Colorado, Boulder

69 total trials

What NCT06776081 shows while recruiting

NCT06776081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Weight loss without pharmacotherapy is the first listed.

NCT06776081 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT06776081 about?

NCT06776081 is a clinical study titled "Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function". Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose ...

What is the current status of trial NCT06776081?

This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2024-07-01. Estimated completion is 2027-06-30.

What conditions does trial NCT06776081 study?

This clinical trial studies the following conditions: Obesity, Weight Loss.

What interventions are being tested in trial NCT06776081?

The interventions under investigation include: Weight loss without pharmacotherapy (OTHER).

Who is sponsoring clinical trial NCT06776081?

This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06776081 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06776081's enrollment target sits among peer trials

84 534th of 1053 higher than 516 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06776081, the US trial registry maintained by the National Library of Medicine. NCT06776081 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.